GlassScriptPhysician profile
David Gandell
NPI 1407811326
$9,806.90
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,938 · 2020: $235 · 2021: $634.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $4,710.72 | 2019-2021 | |
| Duchesnay USA Incorporated | $2,145.06 | 2019 | |
| Amag Pharmaceuticals, INC. | $960.92 | 2019 | |
| Gen-Probe, INC. | $557.77 | 2019 | |
| Abbvie INC. | $451.69 | 2019-2020 | |
| Fujirebio Diagnostics, Incorporated | $350.00 | 2019 | |
| Exeltis, USA INC. | $187.09 | 2020-2021 | |
| Allergan, INC. | $142.78 | 2019 | |
| Therapeuticsmd, INC. | $127.98 | 2019 | |
| Amgen INC. | $120.04 | 2019 | |
| Pfizer INC. | $40.97 | 2020 | |
| Coopersurgical, INC. | $11.88 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gandell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.